Scientists at Boston University have developed a blood test that may be able to detect chronic traumatic encephalopathy, or CTE, in living patients — a disease that until now could only be confirmed by examining brain tissue after death.
The research, led by teams at Boston University and Banner Health, is drawing attention nationally, but it has particular weight in Massachusetts, where BU’s CTE Center has become one of the country’s leading hubs for studying the brain disease linked to repeated head trauma in football and other contact sports.
“This is a game changer,” said Michael Alosco, co-director of clinical research at the Boston University CTE Center and an author of the new study.
CTE has been found in as many as 1 in 4 former NFL players, according to recent research, and can lead to serious changes in personality and cognition, including addiction, psychosis and violence. It has also been linked to a higher risk of ALS. Until now, the only confirmed way to diagnose it has been to examine brain tissue after a patient’s death, leaving athletes and families without a way to identify the disease — or seek treatment — while someone is still alive.
How the study worked
The BU-led research team examined 21 former American football players. Each had blood drawn while alive and later donated their brains for examination after death.
Of those samples, 18, or 85%, were found to have CTE. Of those 18, 16, or 88%, had more severe disease — classified as stage 3 or 4. High-stage CTE has been diagnosed in athletes who died as young as their early 20s, though it is more commonly found in older patients.
The group included players at different levels: 11 of 12 professional players, four of seven college players, and one of two high school players in the study had high-stage CTE.
The biomarker behind the test
Higher-stage CTE is associated with dense buildups of an abnormal protein called p-tau in the brain, which disrupts cell function and drives neurodegeneration — a process also seen in Alzheimer’s disease and frontotemporal dementia. When more of that protein accumulates, the blood contains higher levels of a biomarker known as endogenously cleaved microtubule-binding region tau, or eMTBR-tau, which is already used to help identify Alzheimer’s.
Researchers wanted to know if the same biomarker could signal CTE. Their results suggest it can: eMTBR-tau levels were significantly higher in people with higher-stage CTE, but not elevated in those with low-stage CTE or no CTE at all. Some samples showed former players had both CTE and Alzheimer’s, and those individuals had the highest eMTBR-tau levels of all.
People with CTE may experience memory loss, confusion, difficulty making decisions, irritability, aggression and depression, as well as movement problems such as tremors or balance issues. Currently, doctors can only rule out other causes of these symptoms — they cannot confirm CTE in a living patient.
Still early, but promising
Alosco cautioned that the test is not ready for clinical use. “We are still in the discovery phase and it’s a small sample size, but if future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment,” he said.
Researchers say future studies will need to include hundreds more participants across varying stages of CTE, including those who also have Alzheimer’s.
There is currently no treatment for CTE, and the disease worsens over time. Doctors can offer cognitive therapy to help with memory and attention, behavioral therapy for mood issues, and medication for depression, sleep problems and pain.
Nicholas Ashton, another author on the study, pointed to the impact blood testing has already had for a different disease. “A blood test has been revolutionary” in diagnosing and treating Alzheimer’s disease, he said. “With this new study, we are optimistic that the same will be true for CTE.”
You must be logged in to post a comment Login